CINCOR PHARMA INC (CINC) Stock Price, Quote, News and Overview
NASDAQ:CINC - Nasdaq - US17240Y1091 - Common Stock - Currency: USD
CINC Quote, Performance and Key Statistics
29.06
-0.14 (-0.48%)
The current stock price of CINC is 29.06 USD. In the past month the price increased by 1.15%. In the past year, price increased by 2%.
CINC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About CINC
Company Profile
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The company is headquartered in Waltham, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). The company also exploring its utility in ameliorating complications of CKD. The company is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.
Company Info
CINCOR PHARMA INC
230 Third Ave., 6Th Floor
Waltham MASSACHUSETTS US
Employees: 19
Company Website: https://www.cincor.com/
Phone: 18445311834.0
CINCOR PHARMA INC / CINC FAQ
What is the stock price of CINCOR PHARMA INC today?
The current stock price of CINC is 29.06 USD. The price decreased by -0.48% in the last trading session.
What is the ticker symbol for CINCOR PHARMA INC stock?
The exchange symbol of CINCOR PHARMA INC is CINC and it is listed on the Nasdaq exchange.
On which exchange is CINC stock listed?
CINC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CINCOR PHARMA INC stock?
12 analysts have analysed CINC and the average price target is 39.78 USD. This implies a price increase of 36.89% is expected in the next year compared to the current price of 29.06. Check the CINCOR PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CINCOR PHARMA INC worth?
CINCOR PHARMA INC (CINC) has a market capitalization of 1.27B USD. This makes CINC a Small Cap stock.
How many employees does CINCOR PHARMA INC have?
CINCOR PHARMA INC (CINC) currently has 19 employees.
What are the support and resistance levels for CINCOR PHARMA INC (CINC) stock?
CINCOR PHARMA INC (CINC) has a support level at 29.05 and a resistance level at 29.09. Check the full technical report for a detailed analysis of CINC support and resistance levels.
Should I buy CINCOR PHARMA INC (CINC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CINC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CINC, evaluating the profitability, health, valuation and growth aspects
- CINCOR PHARMA INC (CINC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CINCOR PHARMA INC (CINC) Sales and EPS estimates to see what analysts future expectations are.
- CINCOR PHARMA INC (CINC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CINCOR PHARMA INC (CINC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CINCOR PHARMA INC (CINC) Stock Chart to make your own analysis
- CINCOR PHARMA INC (CINC) Latest news and press-releases to stay up to date.
Does CINCOR PHARMA INC (CINC) stock pay dividends?
CINC does not pay a dividend.
What is the Price/Earnings (PE) ratio of CINCOR PHARMA INC (CINC)?
CINCOR PHARMA INC (CINC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.28).
CINC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CINC. When comparing the yearly performance of all stocks, CINC is one of the better performing stocks in the market, outperforming 81.02% of all stocks.
CINC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CINC. No worries on liquidiy or solvency for CINC as it has an excellent financial health rating, but there are worries on the profitability.
CINC Financial Highlights
Over the last trailing twelve months CINC reported a non-GAAP Earnings per Share(EPS) of -17.28. The EPS decreased by -125.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CINC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to CINC. The Buy consensus is the average rating of analysts ratings from 12 analysts.